Fig. 6: Galangin 3-methyl ether (G3-ME) inhibits pathological cardiac hypertrophy by regulating the PI3K-AKT signaling pathways. | Acta Pharmacologica Sinica

Fig. 6: Galangin 3-methyl ether (G3-ME) inhibits pathological cardiac hypertrophy by regulating the PI3K-AKT signaling pathways.

From: Galangin 3-methyl ether alleviates mouse hypertrophic cardiomyopathy via targeting HDAC2 and subsequently inactivating the PI3K-AKT signaling pathway

Fig. 6: Galangin 3-methyl ether (G3-ME) inhibits pathological cardiac hypertrophy by regulating the PI3K-AKT signaling pathways.

a Schematic diagram for exploring the key targets and signaling pathways of G3-ME. b Principal component analysis (PCA) of the angiotensin II (Ang II)-treated and the G3-ME + Ang II-treated RNA sequence. c Heatmap of differential genes. d KEGG enrichment analysis according to differential genes. e–i The protein expression levels of p-P85, P85, p-AKT, and AKT in H9c2, hESC-CMs, and cardiac tissues of wild-type (WT) or Myh6R404Q mice. n = 4 per group. The values are mean ± SEM. *P < 0.05.

Back to article page